SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant ...
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces the sale of its ChromaDex ...
NEXT WEEK ARE NOW GOING TO BE DELAYED. I.V. FLUID IS LIKE A LIFELINE TO PATIENTS. THAT LIFELINE IS IN SHORT SUPPLY AND NOW IMPACTING PATIENTS WHO HAVE NON-EMERGENCY SURGERIES SCHEDULED AT MASS.
Investing.com -- Johnson & Johnson (NYSE:JNJ) announced Monday that the European Commission has approved subcutaneous Rybrevant (amivantamab) for every-three-week and every-four-week dosing schedules ...
Intravenous use as a QIDP for adjunct treatment of complicated bacteremia caused by Staphylococcus aureus QIDP Designation provides for five years of market exclusivity ...
Acute urticaria is characterized by the wheals or angioedema -- i.e., deeper swelling within the skin or mucus membranes in about 10% of cases, or by both in about 40% of cases. Angioedema can be skin ...
This week, the Billboard charts reflect a post-Grammys surge — as well as the relative calm before the storm of Bad Bunny's Super Bowl halftime show. So it's no surprise that the Puerto Rican ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International stock ...
A new chart showing the U.S. dollar’s crashing value has sparked concern online, reflecting widespread economic uncertainty across the country. The U.S. dollar index measures the U.S. dollar's value ...
This week, we've finally received an infusion of fresh blood in the form of a brand-new album and a brand-new song — by two different artists, no less! — debuting at No. 1. On the albums chart, the ...
EXO’s latest comeback is off to a strong start! On January 19 at 6 p.m. KST, EXO made their long-awaited return with their eighth studio album “REVERXE” and its title track “Crown.” Immediately upon ...
What happened in 2025? Well, a lot. There were tariffs, breakthroughs and disappointments with AI, and a wobbly economy that sent decidedly mixed signals. There were crises of purpose, execution, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results